DiagnaMed Holdings Corp.

As of June 30, 2026, DiagnaMed Holdings Corp. carries a market capitalization of 6.58M, placing it among publicly traded companies globally. Its enterprise value stands at 6.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, DiagnaMed Holdings Corp. has 131.61M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, DiagnaMed Holdings Corp. maintains a current ratio of 0.65, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -599.33, reflecting losses generated across the asset base.

As of the close on October 15, 2026, DiagnaMed Holdings Corp.'s stock has declined approximately 71.43% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.07.

Over the twelve months ended June 30, 2026, DiagnaMed Holdings Corp. generated - - in revenue and converted that into -1.85M in net income, yielding earnings per share of -0.02. EBITDA reached -1.83M, while operating income came in at -1.85M.

These figures are as of June 30, 2026. Total book value stands at -178,004.00, with working capital of -178,004.00 providing operational flexibility.

DiagnaMed Holdings Corp. produced -582,728.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.28: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.35, meaning DiagnaMed Holdings Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, DiagnaMed Holdings Corp. has an Altman Z-Score of -43.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.